NASDAQ:COGT Cogent Biosciences Q1 2025 Earnings Results & Report $27.85 +0.41 (+1.49%) Closing price 04:00 PM EasternExtended Trading$28.00 +0.15 (+0.54%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cogent Biosciences beat analyst earnings expectations in its Q1 2025 results, released May 6, 2025. The company reported EPS of -$0.52 versus the -$0.56 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 6, 2025TimeBefore Market OpensConference Call8:00 AM ET Cogent Biosciences EPS ResultsActual EPS-$0.52Consensus EPS -$0.56Beat/MissBeat by +$0.04One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersCogent Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cogent Biosciences Q1 2025 Earnings FAQ Did Cogent Biosciences beat earnings estimates for Q1 2025? Cogent Biosciences (NASDAQ:COGT) reported earnings of -$0.52 per share for Q1 2025, beating the consensus estimate of -$0.56. The report was announced on Tuesday, May 6, 2025. Cogent Biosciences Earnings HeadlinesCogent Biosciences, Inc. (COGT) Presents at UBS Global Biopharma Conference 2026 TranscriptNovember 17 at 11:00 AM | seekingalpha.comHC Wainwright Cuts Earnings Estimates for Cogent BiosciencesNovember 13, 2026 | americanbankingnews.comLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for $29.97, but it's available as a free download for a limited time.November 17 at 1:00 AM | Profits Run (Ad)Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Humana (HUM)November 11, 2026 | theglobeandmail.comHC Wainwright Forecasts Strong Price Appreciation for Cogent Biosciences (NASDAQ:COGT) StockNovember 11, 2026 | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Share Price Breaks Above 50-Day Moving Average After Earnings MissNovember 11, 2026 | americanbankingnews.comSee More Cogent Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email. Email Address About Cogent BiosciencesCogent Biosciences (NASDAQ:COGT) is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company’s lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role. Bezuclastinib is investigational and has not been established as a treatment for these diseases. Cogent took its current name in 2020 following a merger with Unum Therapeutics. The company’s activities center on developing and advancing its precision-medicine pipeline through clinical research.View Cogent Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.